CymaBay: Positive Phase 3 Data And Competitive Advantage Established (CBAY)

Medical Research Laboratory: Portrait of a Beautiful Female Scientist in Goggles Using Micro Pipette for Test Analysis. Advanced Scientific Lab for Medicine, Biotechnology, Microbiology Development


CymaBay Therapeutics (NASDAQ:CBAY) had made great progress in advancing the use of its drug seladelpar, because it was able to achieve a successful outcome for its phase 3 study known as RESPONSE, which treated patients with primary biliary

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *